TY - JOUR
T1 - Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project
AU - ROADMAP Consortium
AU - Gallacher, John
AU - de Reydet de Vulpillieres, Frederic
AU - Amzal, Billy
AU - Angehrn, Zuzanna
AU - Bexelius, Christin
AU - Bintener, Christophe
AU - Bouvy, Jacoline C.
AU - Campo, Laura
AU - Diaz, Carlos
AU - Georges, Jean
AU - Gray, Alastair
AU - Hottgenroth, Antje
AU - Jonsson, Pall
AU - Mittelstadt, Brent
AU - Potashman, Michele H.
AU - Reed, Catherine
AU - Sudlow, Cathie
AU - Thompson, Robin
AU - Tockhorn-Heidenreich, Antje
AU - Turner, Andrew
AU - van der Lei, Johan
AU - Visser, Pieter Jelle
N1 - Funding Information: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. It is also supported by the Medical Research Council Dementias Platform UK (MR/L023784/1 and MR/009076/1). The authors would like to acknowledge Dr. Sue Chambers and Karen Goa (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company. They would also like to acknowledge the ROADMAP contributors: University of Oxford, UK; National Institute for Health and Care Excellence (NICE), UK; Erasmus Universitair Medisch Centrum Rotterdam, the Netherlands; Universiteit Maastricht, the Netherlands; Synapse Research Management Partners SL, Spain; Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina, Spain; Københavns Universitet, Denmark; Alzheimer Europe, Luxembourg; University of Edinburgh, UK; Goeteborgs Universitet, Sweden; Aarhus Universitet, Denmark; London School of Economics and Political Science, UK; Agentschap College ter Beoordeling van Geneesmiddelen/Medicines Evaluation Board, the Netherlands; IXICO Technologies Ltd, UK; Rijk-suniversiteit Groningen, the Netherlands; Novartis Pharma AG, Switzerland; Eli Lilly and Company Ltd, UK; Biogen Idec Ltd, UK; F. Hoffmann-La Roche Ltd, Switzerland; Janssen Pharmaceutica NV, Belgium; GE Healthcare Ltd, UK; AC Immune SA, Switzerland; Takeda Development Centre Europe Ltd, UK; H. Lundbeck A/S, Denmark; Leids Uni-versitair Medisch Centrum, the Netherlands; Centre Hospitalier Universitaire de Bordeaux, France. Publisher Copyright: © 2019 IOS Press and the authors. All rights reserved. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
AB - ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
KW - Alzheimer's disease
KW - data sharing
KW - data systems
KW - health policy
KW - patient outcome assessment
KW - real-world clinical trials
KW - systems integration
UR - http://www.scopus.com/inward/record.url?scp=85060655878&partnerID=8YFLogxK
U2 - https://doi.org/10.3233/JAD-180370
DO - https://doi.org/10.3233/JAD-180370
M3 - Review article
C2 - 30584137
SN - 1387-2877
VL - 67
SP - 495
EP - 501
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 2
ER -